BioVie Inc. Warrant
BIVIW$0.44 -0.09 (-16.98%)
Company News
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9
BioVie Inc. will host an investor webinar on December 9, 2025, featuring CEO Cuong Do discussing their drug candidates bezisterim and BIV201 for neurological diseases and liver cirrhosis, highlighting clinical progress and potential market opportunities.
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie Inc. will host an investor webinar discussing its drug therapies for neurological diseases, focusing on bezisterim for Alzheimer's, Parkinson's, and long COVID, and BIV201 for liver cirrhosis complications.
